These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38749761)

  • 21. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
    Horiike Y; Suzuki Y; Fujisawa T; Yasui H; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Ogawa N; Suda T
    Rheumatology (Oxford); 2019 Dec; 58(12):2143-2152. PubMed ID: 31143953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of plasma exchange for anti-MDA5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: A case series.
    Watanabe T; Taniguchi M; Ogura S; Asou M; Takayanagi S; Sokai Y; Tsuji Y; Mori KP; Endo T; Nakajima T; Imura Y; Tsukamoto T
    Ther Apher Dial; 2024 Jun; 28(3):432-441. PubMed ID: 38225794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early initiation of plasma exchange therapy for a patient with anti-MDA5 autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease.
    Sasaki N; Ishii A; Kurabayashi T; Sugiyama M; Izumi Y; Nakagome Y; Hirano K; Sasaki S; Kondo Y; Nogi S; Nishikawa A; Hosono Y; Yamada C; Sato S
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):87-94. PubMed ID: 33048020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
    Ye Y; Fu Q; Wang R; Guo Q; Bao C
    J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic plasma exchange for clinically amyopathic dermatomyositis (CADM) associated with rapidly progressive interstitial pneumonia.
    Yamagata A; Arita M; Tanaka A; Tokioka F; Yoshida T; Nishimura K; Ishida T
    J Clin Apher; 2020 Sep; 35(5):435-443. PubMed ID: 32810902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level.
    Osawa T; Morimoto K; Sasaki Y; Matsuda S; Yamana K; Yano R; Uchiyama T; Goto H
    Intern Med; 2018 Feb; 57(3):387-391. PubMed ID: 29093381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-MDA5 Antibody Spectrum in Western World.
    Moghadam-Kia S; Oddis CV; Aggarwal R
    Curr Rheumatol Rep; 2018 Oct; 20(12):78. PubMed ID: 30382445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic analysis of MDA5-associated clinically amyopathic dermatomyositis with interstitial lung disease.
    Wang W; Sun X; Xu Y; Tan W; Liu Y; Zhou J
    Immun Inflamm Dis; 2024 Jun; 12(6):e1332. PubMed ID: 38934403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients.
    Ono N; Kai K; Maruyama A; Sakai M; Sadanaga Y; Koarada S; Inoue T; Tada Y
    Rheumatology (Oxford); 2019 May; 58(5):786-791. PubMed ID: 30541137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
    Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
    Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.
    Gil B; Merav L; Pnina L; Chagai G
    Clin Rheumatol; 2016 Aug; 35(8):2125-2130. PubMed ID: 25846833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BATF2 balances the T cell-mediated immune response of CADM with an anti-MDA5 autoantibody.
    Li C; Liu M; Liu K; Li M; Liu Y; Li T; Wei Y; Long Y; He W; Shi X; Li Y; Zhang H
    Biochem Biophys Res Commun; 2021 Apr; 551():155-160. PubMed ID: 33740622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody.
    Nakashima R; Imura Y; Kobayashi S; Yukawa N; Yoshifuji H; Nojima T; Kawabata D; Ohmura K; Usui T; Fujii T; Okawa K; Mimori T
    Rheumatology (Oxford); 2010 Mar; 49(3):433-40. PubMed ID: 20015976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-MDA-5 negative, anti-Ku positive clinically amyopathic dermatomyositis.
    Carrington AE; Tartar DM; Sivamani RK
    Dermatol Online J; 2021 Apr; 27(4):. PubMed ID: 33999578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis.
    Labrador-Horrillo M; Martinez MA; Selva-O'Callaghan A; Trallero-Araguas E; Balada E; Vilardell-Tarres M; Juárez C
    J Immunol Res; 2014; 2014():290797. PubMed ID: 24741583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
    Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrence in long-term survivor of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis: case series and literature review.
    Suzuki S; Ikeda K; Yamaji K; Tamura N; Morimoto S
    Mod Rheumatol Case Rep; 2021 Jul; 5(2):310-316. PubMed ID: 33560195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies.
    Sato S; Kuwana M; Fujita T; Suzuki Y
    Mod Rheumatol; 2012 Aug; 22(4):625-9. PubMed ID: 22124544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis.
    Li Y; Li Y; Wu J; Miao M; Gao X; Cai W; Shao M; Zhang X; Xu Y; Cong L; He J; Sun X
    J Immunol Res; 2020; 2020():2024869. PubMed ID: 33299896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review.
    González-Moreno J; Raya-Cruz M; Losada-Lopez I; Cacheda AP; Oliver C; Colom B
    Rheumatol Int; 2018 Jul; 38(7):1293-1296. PubMed ID: 29417209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.